Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Receivables (2016 - 2025)

Historic Receivables for ImmunityBio (IBRX) over the last 7 years, with Q3 2025 value amounting to $33.7 million.

  • ImmunityBio's Receivables rose 58717.37% to $33.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.7 million, marking a year-over-year increase of 58717.37%. This contributed to the annual value of $2.7 million for FY2024, which is 3140.17% up from last year.
  • Per ImmunityBio's latest filing, its Receivables stood at $33.7 million for Q3 2025, which was up 58717.37% from $22.3 million recorded in Q2 2025.
  • ImmunityBio's 5-year Receivables high stood at $33.7 million for Q3 2025, and its period low was $2.0 million during Q4 2023.
  • Moreover, its 4-year median value for Receivables was $3.4 million (2024), whereas its average is $8.9 million.
  • Its Receivables has fluctuated over the past 5 years, first plummeted by 3804.51% in 2024, then surged by 98398.06% in 2025.
  • Over the past 4 years, ImmunityBio's Receivables (Quarter) stood at $3.2 million in 2022, then plummeted by 36.71% to $2.0 million in 2023, then rose by 16.89% to $2.4 million in 2024, then soared by 1327.92% to $33.7 million in 2025.
  • Its Receivables stands at $33.7 million for Q3 2025, versus $22.3 million for Q2 2025 and $17.5 million for Q1 2025.